Sepsis is a common complication after severe trauma, infection, shock and major surgery. It has the characteristics of high morbidity, high mortality, and high hospitalization costs. Septic cardiomyopathy is one of the main causes of death in patients with sepsis. This article reviews the pathogenesis and treatment of septic cardiomyopathy. The pathogenesis includes hemodynamics and myocardial changes, mitochondrial fission, cardiomyocyte apoptosis and autophagy, calcium ion imbalance, inflammation mechanism and immune regulation mechanism. The treatment includes conventional treatment, β1 receptor blocker treatment, melatonin, serotonin 3 receptor antagonist, dexmedetomidine and traditional Chinese medicine treatment, etc., aiming to provide a reference for the diagnosis and treatment of septic cardiomyopathy.
As a heterogeneous disease characterized by changes in cardiac structure or function, cardiomyopathy has a significant impact on the quality of life of patients. And the gut microbiota, as the “second genome”, can regulate cardiac function through the “gut-heart axis”, providing a new perspective for the prevention and treatment of cardiomyopathy. This article summarizes the types and quantitative characteristics of gut microbiota in patients with cardiomyopathy. From the perspective of direct effects and indirect effects of metabolites such as short chain fatty acids, trimethylamine oxide, and bile acids, the mechanisms by which gut microbiota affects cardiomyopathy are explained. And the therapeutic effects of various gut microbiota regulation methods, such as dietary regulation, traditional Chinese medicine regulation, probiotics and prebiotics regulation on cardiomyopathy are explored, in order to provide reference for scientific regulation of gut microbiota in the prevention and treatment of cardiomyopathy.